glp-1 and vertigo drugs tied to elevated risk of low blood pressure episodes The Risk of Vestibular Disorders

A recent study involving 3,390 people taking semaglutide or liraglutide found participants who took high doses of their drug 1.7 mg, 2.0 mg or 2.4 mg of semaglutide, or 3 mg of liraglutide lost more weight after a year compared to people taking lower doses

One note specific to Zepbound and Mounjaro: a direct provider consultation may be required before prescribing - not just an intake review

Though more research is definitely warranted to look at the mechanisms by which GLP-1 medications may work, I have seen some studies indicating that it may be a reduction in chronic inflammation, said Ali

The BMI requirement is based on when you started GLP-1 treatment , not necessarily when you apply for the Bridge Program

These studies also demonstrate an association of the fecal and cecal SCFA levels with the expansion of the gut surface area 5

These changes warrant urgent evaluation and may mean your lamotrigine dose or semaglutide formulation needs adjustment